As of May 2024 Galapagos NV has a market cap of $1.89 Billion. This makes Galapagos NV the world's 4223th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $1.89 B | -29.3% |
2023 | $2.67 B | -8.32% |
2022 | $2.92 B | -20.02% |
2021 | $3.65 B | -43.58% |
2020 | $6.47 B | -52.07% |
2019 | $13.50 B | 169.16% |
2018 | $5.01 B | 4.51% |
2017 | $4.80 B | 61.16% |
2016 | $2.97 B | 20.89% |
2015 | $2.46 B | 331.92% |
2014 | $0.57 B | -8.94% |
2013 | $0.62 B | 10.91% |
2012 | $0.56 B | 58.44% |
2011 | $0.35 B | -16.16% |
2010 | $0.42 B | 66.9% |
2009 | $0.25 B | 148.04% |
2008 | $0.10 B |
On May 13th, 2024 the market cap of Galapagos NV was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $363.93 B | 19,116.78% | ๐บ๐ธ USA |
Abbott Laboratories ABT | $182.26 B | 9,523.81% | ๐บ๐ธ USA |
AbbVie ABBV | $284.79 B | 14,938.08% | ๐บ๐ธ USA |
Sanofi SNY | $127.06 B | 6,609.59% | ๐ซ๐ท France |
Merck MRK | $327.46 B | 17,191.02% | ๐บ๐ธ USA |
AstraZeneca AZN | $240.17 B | 12,581.87% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $93.41 B | 4,832.71% | ๐ฌ๐ง UK |
Fortress Biotech
FBIO | $32.69 M | -98.27% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $19.11 B | 909.53% | ๐ฎ๐ฑ Israel |